News

Born with congenital heart disease, 41-year-old Christin Murphy has undergone three heart surgeries to repair pulmonary valves. They have been tough to get through, but Murphy says this latest one at Saint Luke’s changed her outlook.

Since the first SGLT2 inhibitor drug was approved in 2013, the medications have gone from targeting glucose-lowering to also providing cardiac protection and heart benefits.

A study led by Saint Luke’s Mid America Heart Institute researchers found drastic improvements following the American Heart Association’s IMPLEMENT-HF Initiative.

Melissa Magwire, RN, MSN, CDE, discusses the interrelated conditions of diabetes and cardiometabolic disease and how the Cardiometabolic Center of Excellence is changing the game for treatment.

Dr. James O’Keefe and Dr. Andrew Sauer with Saint Luke’s Mid America Heart Institute talk about new research that is changing the way obesity is treated and understood.

Dr. James O’Keefe, a co-investigator of this study, explains why GLP-1 medications may be uniquely effective in addressing addictive behaviors like recreational drug use, alcohol consumption, and food cravings.

This week we're talking with Dr. Sanjaya Gupta, cardiologist at Saint Luke’s Mid America Heart Institute, about the latest treatment options for this underdiagnosed heart condition.

Dr. Adnan Chhatriwalla, interventional cardiologist at Saint Luke’s Mid America Heart Institute, talks about symptoms of heart valve disease, treatment, and keys to long-term heart health.

According to a new study, higher omega-3 levels significantly reduce the risk of heart failure and heart failure fatalities.

TIME talked to Dr. James O'Keefe about research that found tennis can positively impact a person's longevity.